# **Vertigo severity, comorbidity burden, and hearing status** can influence **treatment response** among patients with **Meniere's disease**



# Identifying Predictors of Treatment Response in Meniere's Disease: A Clinical Severity Staging System

Brevin J. Miller, BA<sup>1</sup>; Dorina Kallogjeri, MD, MPH<sup>1</sup>; Matthew A. Shew, MD<sup>2</sup>; Jay F. Piccirillo, MD, FACS<sup>1</sup>

## INTRODUCTION

- Meniere's disease (MD) negatively impacts quality of life<sup>1-3</sup>
- Treatment recommendations are often heterogeneous and treatment response is difficult to predict<sup>4,5</sup>
- Objective: Identify predictors of response to conservative treatments and integrate this information into a clinical severity staging system

#### **METHODS**

- Design: Retrospective cohort study
- Population: Patients newly-diagnosed with MD in 2016-2019
- Primary Outcome: Response to conservative treatment
- Disease-related and comorbid factors were compared between treatment responders and nonresponders
- Clinically important factors were identified and integrated into a clinical severity staging system through conjunctive consolidation<sup>6-8</sup>

### **RESULTS**

Clinical Characteristics of Treatment Responders and Nonresponders

Characteristics	No. (%)		
	Treatment Responders (n=49)	Treatment Nonresponders (n=29)	
Age, mean (SD), years	55 (11)	56 (13)	
Sex			
Female	28 (57)	15 (52)	
Male	21 (43)	14 (48)	
Vertigo Severity			
None/Mild	26 (53)	8 (28)	
Moderate	13 (27)	10 (34)	
Severe	10 (20)	11 (38)	
Comorbidity Burden			
None/Mild	47 (96)	20 (69)	
Moderate/severe	2 (4)	9 (31)	
Hearing Loss			
Present	38 (78)	28 (97)	
Absent	11 (22)	1 (3)	

• Overall, 49 of 78 (63%) patients were responsive to conservative treatment

# CONCLUSIONS

- Patients with less severe vertigo, few comorbidities, and no subjective hearing loss may be more likely to respond to conservative treatments
- The development of a clinical severity staging system provides patient-level insight into therapeutic response
- This staging system can be used as a tool to help guide treatment selection and in provider-patient counseling and decision-making

Development of Otovestibular Severity Staging System (OSSS)

Vertigo	Hearing Loss		Total
Severity	Absent	Present	
None/Mild	7/7 (100)	19/27 (70)	26/34 (76)
Moderate	2/2 (100)	11/21 (50)	13/23 (58)
Severe	2/3 (67)	8/18 (44)	10/21 (48)
Total	11/12 (92)	38/66 (58)	49/78 (63)

Otovestibular Staging System (OSSS)		
Alpha	11/12 (92)	
Beta	19/27 (70)	
Gamma	19/39 (49)	

Development of the Clinical Severity Staging System (CSSS)

OSSS Comorbidity Burden		Total	
	None/Mild	Moderate/ Severe	
Alpha	11/11 (100)	0/1 (0)	11/12 (92)
Beta	18/25 (72)	1/2 (50)	19/27 (70)
Gamma	18/31 (58)	1/8 (12)	19/39 (49)
Total	47/67 (70)	2/11 (18)	49/78 (63)

Clinical Severity Staging System (CSSS)		
Stage 1	11/11 (100)	
Stage 2	36/56 (64)	
Stage 3	2/11 (18)	

Washington University in St. Louis
School of Medicine

<sup>1</sup>Clinical Outcomes Research Office, Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St. Louis


<sup>2</sup>Division of Otology & Neurotology, Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St. Louis

Clinical Research
Training Center

This research was supported by the National Institute of Deafness and Other Communication Disorders within the National Institutes of Health, through the "Development of Clinicians/Researchers in Academic ENT" training grant, award number T32DC000022.

Full Abstract & References





**◄** Published article